Tadalafil Tablet, Film Coated
Product Images NDC 33342-266

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 33342-266). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Macleods Pharmaceuticals Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Tadalafil-10mg-30-container (Tadalafil 10mg 30 Container)

Label for Tadalafil Tablets, USP 10 mg film-coated tablets by Macleods Pharmaceuticals Limited. The label includes dosage strength 10 mg, 30 tablets per package, manufacturer information for Macleods Pharma USA, Inc. and Macleods Pharmaceuticals Ltd., Daman, India. It also contains storage instructions and warnings about tablet splitting and keeping out of reach of children.*

FDA Label Image

Tadalafil-2-5mg-30-container (Tadalafil 2 5mg 30 Container)

Label for Tadalafil Tablets, USP 2.5 mg film-coated tablets, indicated for once daily use. The label shows the 2.5 mg strength, a package size of 30 tablets, and instructions not to split tablets. It also includes storage instructions and manufacturing details by Macleods Pharmaceuticals Ltd and Macleods Pharma USA, Inc.*

FDA Label Image

Tadalafil-20mg-30-container (Tadalafil 20mg 30 Container)

Label for Tadalafil Tablets USP 20 mg film coated tablets by Macleods Pharmaceuticals Limited. The label includes dosage strength, quantity of 30 tablets, manufacturer details from Macleods Pharma USA and Macleods Pharmaceuticals Ltd, usage warnings, storage instructions, and barcodes. The label also notes that tablets should not be split and the entire dose should be taken.*

FDA Label Image

Tadalafil-5mg-30-container (Tadalafil 5mg 30 Container)

Label for Tadalafil Tablets USP 5 mg film-coated tablets by Macleods Pharmaceuticals Limited. The label includes the drug name, strength (5 mg), dosage form (tablets), quantity (30 tablets), storage instructions, warnings, and manufacturing information for Macleods Pharma USA, Inc. The label also includes barcodes and a note that tablets should not be split and entire dose should be taken.*

FDA Label Image

Fig1 (Tadalafil Figure 1)

This figure contains four line graphs displaying blood pressure changes over time in hours. The top left graph shows standing systolic blood pressure differences between tadalafil and placebo. The top right graph shows standing diastolic blood pressure differences. The bottom left graph shows supine systolic blood pressure differences, and the bottom right graph shows supine diastolic blood pressure differences over the same time period. Error bars indicate variability at each time point.*

FDA Label Image

Fig (Tadalafil Figure 2)

A figure consisting of two line graphs showing changes in systolic blood pressure (mmHg) over 24 hours post-dose (h). The top graph displays standing systolic blood pressure, and the bottom graph shows supine systolic blood pressure. Both graphs compare Tadalafil 20 mg plus doxazosin 8 mg versus placebo plus doxazosin 8 mg, with time on the x-axis and blood pressure on the y-axis.*

FDA Label Image

Fig (Tadalafil Figure 3)

A line graph showing the effects on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil or placebo combined with 8 mg daily doxazosin at two different times (08:00 and 20:00). The chart compares 20 mg tadalafil versus placebo for each dosing time, illustrating blood pressure changes over time.*

FDA Label Image

Fig (Tadalafil Figure 4)

A pharmacokinetic graph showing plasma concentration of Tadalafil (µg/L) over time (hours). It compares single 20 mg and 5 mg doses, and once-daily 5 mg dosing after 5 days, with error bars indicating variability in plasma levels over approximately 120 hours.*

FDA Label Image

Fig (Tadalafil Figure 5)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Tadalafil 5 mg tablets and placebo. The x-axis shows treatment duration in weeks (0, 4, 8, 12), and the y-axis shows change in score. Tadalafil shows a greater reduction over time compared to placebo, with statistical significance indicated at p<0.01.*

FDA Label Image

Fig (Tadalafil Figure 6)

A line graph comparing change from baseline in IPSS Total Score over a 12-week treatment duration between Tadalafil 5 mg tablets and placebo groups. The X-axis represents treatment duration in weeks, and the Y-axis shows the change in IPSS score, with Tadalafil showing a greater reduction compared to placebo, with statistical significance at week 4 (p<0.01).*

FDA Label Image

Fig (Tadalafil Figure 7)

A line graph depicting the least-squares (LS) mean change from baseline over 26 weeks of therapy, comparing Tadalafil/Finasteride and Placebo/Finasteride treatment groups. The x-axis represents weeks of therapy (0, 4, 12, 26), and the y-axis measures LS mean change values from 0 to -7. Data points include statistical significance markers 'a' (p<0.001) and 'b' (p<0.05). The graph illustrates greater LS mean decreases for the Tadalafil/Finasteride group compared to Placebo/Finasteride.*

FDA Label Image

Fig (Tadalafil Figure 8)

A line graph comparing change from baseline in IPSS total score over a 12-week treatment duration between Tadalafil Tablets 5 mg and placebo groups. The x-axis represents treatment duration in weeks, and the y-axis shows the change in IPSS score. The Tadalafil group shows a greater reduction in score compared to placebo, with statistical significance indicated.*

FDA Label Image

Stru (Tadalafil Structure)

Chemical structure diagram of the active ingredient tadalafil, showing its molecular framework with multiple rings including an indole and a tetrahydrofuran moiety.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.